Matthew A. Cooper
Founder at Inflazome Ltd.
Matthew A. Cooper active positions
| Companies | Position | Start | End |
|---|---|---|---|
Inflazome Ltd.
 Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland. | Director/Board Member | 2015-12-31 | - |
| Chief Executive Officer | 2015-12-31 | - | |
| Founder | 2015-12-31 | - | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Private Equity Investor | 2022-07-19 | - |
Career history of Matthew A. Cooper
Former positions of Matthew A. Cooper
| Companies | Position | Start | End |
|---|---|---|---|
Akubio Ltd.
 Akubio Ltd. Electronic Equipment/InstrumentsElectronic Technology Akubio Ltd. develops acoustic biosensor instruments. Its products are used in protein research and drug development. The company's technology based on quartz resonators delivers molecular identification and measurement of interactions in complex samples. Akubio was founded by Matthew A. Cooper in August 2001 and is headquartered in Cambridge, UK | Chief Tech/Sci/R&D Officer | 2001-07-31 | 2010-05-30 |
| Founder | 2001-07-31 | 2010-05-30 | |
| University of Cambridge | Corporate Officer/Principal | - | - |
Training of Matthew A. Cooper
| University of Adelaide | Doctorate Degree |
Statistics
International
| United Kingdom | 3 |
| Australia | 2 |
| Ireland | 2 |
Operational
| Founder | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sectoral
| Consumer Services | 3 |
| Electronic Technology | 2 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 3 |
|---|---|
Akubio Ltd.
Akubio Ltd. Electronic Equipment/InstrumentsElectronic Technology Akubio Ltd. develops acoustic biosensor instruments. Its products are used in protein research and drug development. The company's technology based on quartz resonators delivers molecular identification and measurement of interactions in complex samples. Akubio was founded by Matthew A. Cooper in August 2001 and is headquartered in Cambridge, UK | Electronic Technology |
Inflazome Ltd.
Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland. | Health Technology |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Finance |
- Stock Market
- Insiders
- Matthew A. Cooper
- Experience
